Maxim Group analyst Caroline Palomeque maintained a Buy rating on Daré Bioscience Inc (DARE) today and set a price target of $3. The company’s shares opened today at $0.67, close to its 52-week low of $0.60.
Palomeque noted:
“Management provided an update on its anticipated catalyst timelines for its Women’s Health pipeline programs in 2019. Focus will be on its two late-stage programs; and its recently acquired Phase 3-ready asset, DARE-BV-1, for bacterial vaginosis.”
According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -23.9% and a 17.8% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Daré Bioscience Inc with a $3 average price target.
See today’s analyst top recommended stocks >>
Based on Daré Bioscience Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.57 million. In comparison, last year the company had a GAAP net loss of $9.13 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Daré Bioscience, Inc. operates as a healthcare company. It engages in the development and commercialization of pharmaceutical products in women’s reproductive health. Its products inclide Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in La Jolla, CA.
